EP1153940A1 — Polymer combining with phosphoric acid and preparation containing the same
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2001-11-14 · 25y expired
What this patent protects
Disclosed are a phosphate-binding polymer having a true specific gravity of 1.18 - 1.24, tablets that solely consist of the particles of a phosphate-binding polymer having an average particle size of no more than 400 µm, with at least 90% being occupied by particles no larger tha…
USPTO Abstract
Disclosed are a phosphate-binding polymer having a true specific gravity of 1.18 - 1.24, tablets that solely consist of the particles of a phosphate-binding polymer having an average particle size of no more than 400 µm, with at least 90% being occupied by particles no larger than 500 µm, and having a true specific gravity of 1.18-1.24 and a water content of 1 - 14%, or tablets that contain both the particles and crystalline cellulose and/or low substituted hydroxypropyl cellulose, and a process for producing such tablets. The phosphate-binding polymer can be formulated as tablets either alone or in combination with specified additives. Whichever the case, the tablets have satisfactory hardness, contain the active ingredient in high proportion, have high phosphate-binding capability and exhibit rapid disintegrability in an acidic to neutral region while having little sensitivity to the strength of agitation. The tablets are excellent pharmaceutical preparations that undergo reduced variations in bioavailability in spite of movements within the digestive tracts and pH changes.
Drugs covered by this patent
- Renvela (SEVELAMER CARBONATE) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.